The Week in Cancer News: Young Adult Palliative Care
Palliative care services are underused in young adults with advanced cancer, and a campaign aims to raise awareness about the fallopian tubes’ role in ovarian cancer.
Progress Against Cancer
Palliative care services are underused in young adults with advanced cancer, and a campaign aims to raise awareness about the fallopian tubes’ role in ovarian cancer.
Lutetium Lu 177 vipivotide tetraxetan is the first radioligand therapy approved for metastatic prostate cancer that responds to hormone treatment. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote...
The summer issue of Cancer Today includes articles about integrating patient-reported outcomes into clinical research and care, advances in preventing and treating graft-versus-host disease, researchers’ efforts to better understand the mechanisms of treatment resistance,...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR; Lillian L. Siu, MD, FAACR; and Timothy...
Zidesamtinib, a next-generation ROS1 inhibitor, was approved for ROS1-positive NSCLC previously treated with ROS1 inhibition. The U.S. Food and Drug Administration (FDA) has approved zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for adults with locally...
At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how...
A targeted therapy inhibits multiple proteins in a common signaling pathway for breast cancer, and disparities researchers feel the impact of shifting federal priorities.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More